Navigation Links
CHS Receives Prestigious Honor from Department of Defense
Date:9/14/2007

eaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE CHS
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... INCLINE VILLAGE, Nev., Sept. 8 PDL BioPharma, ... guidance for the third quarter ended September 30, 2009 of ... third quarter of 2008. Royalty revenues are based on second ... for Synagis(R), which is marketed by MedImmune. When compared with ...
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: ... will present a company update at the Morgan Stanley Healthcare Conference in ... , , Interested parties may access a ... the BioMarin website, www.BMRN.com . A replay of ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... failure gout will be presented at the 2009 ACR/ARHP Annual Scientific ... posters will be presented during the "Treatment and Outcome" session on ... , Chronic Use of Pegloticase: Safety ...
Cached Biology Technology:PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3BioMarin to Present at the Morgan Stanley Healthcare Conference 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... Luxembourg Centre for Systems Biomedicine (LCSB) of the University ... from which differentiated cells for instance skin cells ... cell types such as nerve cells, for example. ... computer-based instructions for reprogramming cells are of huge significance ...
... rats have long since been a standard animal model for ... years on average and high incidence of cancer. Naked mole ... African subterranean rodent has a maximum lifespan exceeding 30 years ... not a single incident of cancer has been detected makes ...
... central nervous system is injured, oligodendrocyte precursor cells (OPC) ... on demyelinated axons. Scientists at the Institute of Molecular ... now discovered that a distinct protein regulates the direction ... protein NG2, which is expressed at the surface of ...
Cached Biology News:Computational biology: Cells reprogrammed on the computer 2The naked mole-rat's secret to staying cancer free 2Scientists at Mainz University decode mechanisms of cell orientation in the brain 2
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
...
...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 9(S)-HODE by GC- or ... of linoleic acid in both plants and animals. ... an esterified component of membrane phospholipids and in ...
Biology Products: